1. Home
  2. OOMA vs ACIU Comparison

OOMA vs ACIU Comparison

Compare OOMA & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ooma Inc.

OOMA

Ooma Inc.

N/A

Current Price

$22.38

Market Cap

565.7M

Sector

Technology

ML Signal

N/A

Logo AC Immune SA

ACIU

AC Immune SA

N/A

Current Price

$2.69

Market Cap

247.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
OOMA
ACIU
Founded
2003
2003
Country
United States
Switzerland
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
565.7M
247.6M
IPO Year
2015
2015

Fundamental Metrics

Financial Performance
Metric
OOMA
ACIU
Price
$22.38
$2.69
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
2
Target Price
$18.77
$10.00
AVG Volume (30 Days)
418.2K
176.3K
Earning Date
05-27-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
188.46
N/A
EPS
0.20
N/A
Revenue
$114,490,000.00
N/A
Revenue This Year
$20.35
$706.75
Revenue Next Year
$4.17
$321.13
P/E Ratio
$113.30
N/A
Revenue Growth
9.53
N/A
52 Week Low
$9.79
$2.10
52 Week High
$26.19
$4.00

Technical Indicators

Market Signals
Indicator
OOMA
ACIU
Relative Strength Index (RSI) 56.18 50.63
Support Level $19.66 $2.57
Resistance Level $23.81 $2.68
Average True Range (ATR) 1.18 0.13
MACD -0.01 -0.02
Stochastic Oscillator 42.97 23.81

Price Performance

Historical Comparison
OOMA
ACIU

About OOMA Ooma Inc.

Ooma Inc is a communications services company. It is a smart software-as-a-service (SaaS) and unified communications platform that delivers voice and collaboration features, including messaging, intelligent virtual attendants, and video conferencing, and residential phone service provides PureVoice high-definition voice quality, advanced functionality and integration with mobile devices. Its services rely upon the following main elements: multi-tenant cloud service, on-premise devices, desktop and mobile applications, and calling platforms. It generates revenues from the sale of subscriptions and other services.

About ACIU AC Immune SA

AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

Share on Social Networks: